Long-Term Effects of Doxazosin, an Alpha1-Blocker, on Serum Lipids in Hypertensive Patients.

Abstract

Nowadays practical antihypertensive therapy involves not only simple normalization of blood pressure but also a reduction of the risks of cardiovascular disease.In this multicenter open-label study, the longterm effects of doxazosin, an al-adrenergic receptor blocker, on serum lipids were prospectively investigated in 253 patients with essential hypertension. They were treated with doxazosin for 1 year. The averaged blood pressure was maintained at levels lower than 150190 mmHg throughout 1 year, but heart rate did not increase. After 3 months of doxazosin therapy, total and low density lipoprotein-cholesterol levels in serum were significantly reduced by 3.3% and 3.4% , respectively, and these levels were maintained throughout the study period. This effect of doxazosin on serum lipids was especially prominent in patients with hypercholesterolemia.In addition, the lipid profile of these patients was favorably altered even when other antihypertensive drugs or lipid-lowering drugs had already been used or were used concurrently.These results constitute useful information for physicians who treat hypertension with alblockers to reduce the overall risk of cardiovascular disease. (Hypertens Res 1996; 19: 43-49)

Add-On Effect of Bedtime Dosing of the .ALPHA.1-Adrenergic Receptor Antagonist Doxazosin on Morning Hypertension and Left Ventricular Hypertrophy in Patients Undergoing Long-Term Amlodipine Monotherapy

“…Significant decreases in the serum total cholesterol and triglycerides levels were observed in this study, consistent with previous reports (43)(44)(45). However, the changes in the serum levels of total cholesterol and triglycerides showed no significant correlations with the changes in the LVMI or RWT.…”

Development and analysis of a comprehensive diagnostic model for aortic valve calcification using machine learning methods and artificial neural networks

“…Doxazosin and Terfenadine demonstrated a negative connection and may treat AVC. Doxazosin, an ana1-adrenergic antihypertensive medication, successfully lowers blood pressure, plasma cholesterol, triglyceride levels and density lipoprotein, while raising high–density lipoprotein ( 75 – 78 ). Decreased oxidized low-density lipoprotein cholesterol may not fully explain Doxazosin’s anti-atherogenic effect, but it may be one of its supplementary weapons for avoiding atherosclerosis in addition to blood pressure and lipid reduction.…”

Advantages of ramipril/amlodipin fixed combination therapy. When should we use it?

“…Ezzel szemben az intrinsic sympathomimeticus aktivitással (ISA) rendelkező béta-blokkolók lényegében nem befolyásolják a lipidszinteket [23]. Az alfa-1-adrenerg blokkolók és az alfa-2-adrenerg agonisták enyhén csökkentik az LDLkoleszterin-szintet [24]. A centrális hatású imidazo lin-1-agonista rilmenidin kedvezően hat a lipidanyag cserére, az összkoleszterint, az LDL-koleszterint és a trigliceridet csökkenti, míg a HDL-koleszterin-szintet emeli [25].…”